NCL Technology Ventures interview on Kent Life Science Fund with Biotechandmoney.com 24 May, 2018

In March 2018, NCL Technology Ventures launched a £50 million fund to help facilitate the growth of the UK’s life sciences sector.

The fund has been set up to provide early-stage investments in high-potential companies with a therapeutic or healthcare technology focus.

NCL is working in partnership with the Institute of Pharmaceutical Science, King’s College London, and the University of Kent to help accelerate the progress of portfolio companies within the

new £50 million Life Science fund.

Discovery Park remains test bed for innovation

The fund is also backed by Kent County Council, building on NCL’s existing relationship with the county, and the success of its first fund, which is based at Discovery Park in Sandwich, Kent.

As with the eight biotech and environmental technology portfolio companies within the first fund, investee companies in the new Life Science fund will have the opportunity to access facilities available at the leading UK science park.

In addition to offering office space, laboratories, and manufacturing facilities, the science park brings together service providers, pharma, and start-ups to create an ecosystem

that nurtures growth and innovation.

Taking science companies on path to commercial success

The Kent Life Science Fund is targeted at companies that have achieved proof of concept, from which point NCL will provide a framework of support that will assist investee companies on their path to commercialisation.

Jonathan Synett, Managing Director, NCL Venture Management, says: “We like to invest early in good platform technology, and look to license and spin out those technologies as they develop.”

Whatever area of life sciences a potential investee company operates in, they must be commercially driven.

“This includes a clear understanding of who the company is developing its technology for.

For a therapeutics company, this means understanding which pharmaceutical companies are interested in the relevant therapeutic area, how active they are in that space, and what deals they have previously undertaken within that space.

Alongside this commercial focus, the strength of the team is also key.  The firm’s framework of support is also designed to ready companies for commercialisation.

The above is an excerpt from an article which originally appeared in Biotechandmoney.com